Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation

Cited 2 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorSang-Hyun Lee-
dc.contributor.authorJ M Kim-
dc.contributor.authorDong Gwang Lee-
dc.contributor.authorJangwook Lee-
dc.contributor.authorJong Gil Park-
dc.contributor.authorTae-Su Han-
dc.contributor.authorHyun-Soo Cho-
dc.contributor.authorYoung Lai Cho-
dc.contributor.authorKwang-Hee Bae-
dc.contributor.authorYoung-Jun Park-
dc.contributor.authorSeon-Jin Lee-
dc.contributor.authorMoo-Seung Lee-
dc.contributor.authorY M Huh-
dc.contributor.authorD Y Jo-
dc.contributor.authorH J Yun-
dc.contributor.authorH J Jeong-
dc.contributor.authorN Kim-
dc.contributor.authorM Joo-
dc.contributor.authorJang Seong Kim-
dc.contributor.authorH J Lee-
dc.contributor.authorJeong Ki Min-
dc.date.accessioned2021-03-12T01:02:06Z-
dc.date.available2021-03-12T01:02:06Z-
dc.date.issued2021-
dc.identifier.issn13509047-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/24172-
dc.description.abstractGallbladder carcinoma (GBC) exhibits poor prognosis due to local recurrence, metastasis, and resistance to targeted therapies. Using clinicopathological analyses of GBC patients along with molecular in vitro and tumor in vivo analysis of GBC cells, we showed that reduction of Dsg2 expression was highly associated with higher T stage, more perineural, and lymphatic invasion. Dsg2-depleted GBC cells exhibited significantly enhanced proliferation, migration, and invasiveness in vitro and tumor growth and metastasis in vivo through Src-mediated signaling activation. Interestingly, Dsg2 binding inhibited Src activation, whereas its loss activated cSrc-mediated EGFR plasma membrane clearance and cytoplasmic localization, which was associated with acquired EGFR-targeted therapy resistance and decreased overall survival. Inhibition of Src activity by dasatinib enhanced therapeutic response to anti-EGFR therapy. Dsg2 status can help stratify predicted patient response to anti-EGFR therapy and Src inhibition could be a promising strategy to improve the clinical efficacy of EGFR-targeted therapy.-
dc.publisherSpringer-Nature Pub Group-
dc.titleLoss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation-
dc.title.alternativeLoss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation-
dc.typeArticle-
dc.citation.titleCell Death and Differentiation-
dc.citation.number0-
dc.citation.endPage4-
dc.citation.startPage628-
dc.citation.volume20-
dc.contributor.affiliatedAuthorSang-Hyun Lee-
dc.contributor.affiliatedAuthorDong Gwang Lee-
dc.contributor.affiliatedAuthorJangwook Lee-
dc.contributor.affiliatedAuthorJong Gil Park-
dc.contributor.affiliatedAuthorTae-Su Han-
dc.contributor.affiliatedAuthorHyun-Soo Cho-
dc.contributor.affiliatedAuthorYoung Lai Cho-
dc.contributor.affiliatedAuthorKwang-Hee Bae-
dc.contributor.affiliatedAuthorYoung-Jun Park-
dc.contributor.affiliatedAuthorSeon-Jin Lee-
dc.contributor.affiliatedAuthorMoo-Seung Lee-
dc.contributor.affiliatedAuthorJang Seong Kim-
dc.contributor.affiliatedAuthorJeong Ki Min-
dc.contributor.alternativeName이상현-
dc.contributor.alternativeName김진만-
dc.contributor.alternativeName이동광-
dc.contributor.alternativeName이장욱-
dc.contributor.alternativeName박종길-
dc.contributor.alternativeName한태수-
dc.contributor.alternativeName조현수-
dc.contributor.alternativeName조영래-
dc.contributor.alternativeName배광희-
dc.contributor.alternativeName박영준-
dc.contributor.alternativeName이선진-
dc.contributor.alternativeName이무승-
dc.contributor.alternativeName허용민-
dc.contributor.alternativeName조덕연-
dc.contributor.alternativeName윤환정-
dc.contributor.alternativeName전흥진-
dc.contributor.alternativeName김나영-
dc.contributor.alternativeName주민아-
dc.contributor.alternativeName김장성-
dc.contributor.alternativeName이효진-
dc.contributor.alternativeName민정기-
dc.identifier.bibliographicCitationCell Death and Differentiation, vol. 20, pp. 628-4-
dc.identifier.doi10.1038/s41418-020-00628-4-
dc.description.journalClassY-
Appears in Collections:
Division of Biomedical Research > Biotherapeutics Translational Research Center > 1. Journal Articles
Division of Research on National Challenges > Stem Cell Convergenece Research Center > 1. Journal Articles
Division of Biomedical Research > Metabolic Regulation Research Center > 1. Journal Articles
Division of Research on National Challenges > Environmental diseases research center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.